The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...
The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback